Background: The CCN (CTGF/Cyr61/NOV) family of genes presently consists of six distinct members, which encode proteins that participate in fundamental biological processes such as cell proliferation, adhesion, migration, differentiation, wound healing, angiogenesis and several pathologies including fibrosis and tumorigenesis. Whereas Cyr61 and CTGF act as positive regulators of cell growth, nov(nephroblastoma overexpressed, CCN3/IGFBP9 or NOVH) provides the first example of a CCN protein with negative regulatory properties and the first example of aberrant expression being associated with tumor development. In animals and humans increased expression of nov is detected in tissues where calcium is a key regulator, such as the adrenal gland, central nervous system, bone and cartilage, heart muscle and kidney. The nov protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway. The gene that expresses nov is located on human chromosome 8q24.12 and was originally cloned following discovery of its avian homolog as a consequence of overexpression in virally induced nephroblastoma.
Description: Rabbit polyclonal to IGFBP9
Immunogen: KLH conjugated synthetic peptide derived from IGFBP9
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 70 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-500;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
